[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-369135-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-369135-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","eno1-promotes-pdac-progression-inhibiting-cd8-t-cell-infiltration-via-upregulating-pd-l1-expression-through-hif-1-signaling","ENO1 promotes PDAC progression - inhibiting CD8+ T cell infiltration via upregulating PD-L1 expression through HIF-1α signaling","","Metabolic reprogramming drives cancer progression, with the Warburg effect and hypoxia shaping pancreatic ductal adenocarcinoma (PDAC) biology and tumor immunity. Under hypoxic conditions, aerobic glycolysis supports nutrient and energy demands while remodeling the tumor microenvironment. This study examines α-enolase (ENO1) in PDAC, showing that ENO1 is highly expressed in patients and correlates with poor prognosis. ENO1 knockdown reduces proliferation and colony formation, enhances apoptosis, and suppresses tumorigenesis in mouse models, while high ENO1 impairs CD8+ T cell infiltration and function. Mechanistically, ENO1 increases PD-L1 via HIF-1α signaling, promoting PDAC progression and suggesting ENO1 as a biomarker and immunotherapeutic target.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/eno1-promotes-pdac-progression-inhibiting-cd8-t-cell-infiltration-via-upregulating-pd-l1-expression-through-hif-1-signaling/369135/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/eno1-promotes-pdac-progression-inhibiting-cd8-t-cell-infiltration-via-upregulating-pd-l1-expression-through-hif-1-signaling/369135.png","ImageObject",300,407,{"name":42,"@type":43},"Lucas Martin","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-13","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",11,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What role does ENO1 play in PDAC progression?","Question",{"text":63,"@type":64},"ENO1 promotes PDAC progression by increasing PD-L1 expression and thereby limiting CD8+ T cell infiltration and function in the tumor microenvironment.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How does ENO1 affect CD8+ T cells in the tumor immune microenvironment?",{"text":68,"@type":64},"High ENO1 expression impairs CD8+ T cell infiltration and function, weakening anti-tumor immunity.",{"name":70,"@type":61,"acceptedAnswer":71},"What mechanism links ENO1 to PD-L1 expression?",{"text":72,"@type":64},"Mechanistic analysis indicates that ENO1 upregulates PD-L1 through the HIF-1α signaling pathway under hypoxic conditions.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},369135,1790323101,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":140,"language":141,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":12,"update_tm":145,"read_time":113,"preview_page_count":33,"preview_urls":146},8796095360427,"https://ap-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d","Translational Oncology 52 (2025) 102261  \nContents lists available at ScienceDirect Translational Oncology  \njournal [homepage:](homepage: www.elsevier.com/locate/tranon)[ www.elsevier.com/locate/tranon](homepage: www.elsevier.com/locate/tranon)  \n| Original Research\u003Cbr>ENO1 promotes PDAC progression by inhibiting CD8+ T cell infiltration through upregulating PD-L1 expression via HIF-1α signaling\u003Cbr>Aziguli Tulamaitia,1, Shu-Yu Xiao a,1, Yan Yanga,1, Musitaba Mutailifua, Xia-Qing Lib, Shi-Qi Yin b, Hong-Tai Mab, Hong-Fei Yaoc, Lin-Li Yao a, Li-Peng Hua, Jun Lia,\u003Cbr>Shu-Heng Jiang a, Zhi-Gang Zhang a, Yan-Miao Huo d,**, Dong-Xue Lia,*, Xue-Li Zhang a,* \u003Cbr>a State Key Laboratory of Systems Medicine for Cancer, Shanghai Cancer Institute, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China\u003Cbr>b Shanghai Fengxian District Central Hospital, School of Medicine, Anhui University of Science and Technology, Shanghai, China\u003Cbr>c Department of Hepato-Biliary-Pancreatic Surgery, General Surgery, Huadong Hospital Affiliated to Fudan University, Shanghai, China d Department of Biliary-Pancreatic Surgery, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, 160 Pujian Road, Shanghai, China |  |\n| --- | --- |\n| A R T I C L E I N F O\u003Cbr>Keywords:\u003Cbr>α-Enolase (ENO1)\u003Cbr>Tumor immune microenvironment (TIME) CD8+ T cells\u003Cbr>PD-L1\u003Cbr>Hypoxia induced factor 1α (HIF-1α) | A B S T R A C T\u003Cbr>Metabolic reprogramming is a hallmark of cancer. The“Warburg effect”, also known as aerobic glycolysis, is an essential part of metabolic reprogramming and a central contributor to cancer progression. Moreover, hypoxia isone of the significant features of pancreatic ductal adenocarcinoma (PDAC). Under hypoxic conditions, the“Warburg effect” occurs to meet the nutrient and energy demands of rapid genome replication, remodeling the tumor microenvironment (TME) and influencing tumor immunity. α-Enolase (ENO1) is a multifunctional protein, acting as a glycolytic enzyme that catalyzes the conversion of 2-phosphoglyceric acid to phosphoenolpyruvic acid. ENO1 was found to be overexpressed in multiple types of cancers. Here, we investigated the role of ENO1 in modulating the PDAC microenvironment.\u003Cbr>Using bioinformatic analyses, we demonstrated that ENO1 was highly expressed in PDAC patients, which was related to a poor prognosis. In vitro, Eno1 knockdown resulted in reduced PDAC cell proliferation and colony formation, along with enhanced apoptosis in PDAC cells. In vivo, tumorigenesis was suppressed in mouse PDAC models by Eno1 knockdown. Flow cytometry analysis revealed that high expression of Eno1 altered the tumor immune microenvironment (TIME), particularly the impaired tumor infiltration and function of CD8+ T cells. Mechanistic studies revealed that ENO1 upregulated PD-L1 to prevent CD8+ T cells infiltration through the hypoxia-inducible factor (HIF)-1α signaling pathway, leading to PDAC progression.\u003Cbr>In conclusion, our findings indicate that ENO1 might serve as a potential biomarker for PDAC and a novel onco-immunotherapeutic target via its role in altering the TIME. |\n\nIntroduction  \nAs per the 2022 statistics from the Global Cancer Observatory (GLOBOCAN), pancreatic cancer is the 12th most commonly diagnosed malignant tumor and the 6th leading cause of cancer-related deaths [1]. Pancreatic ductal adenocarcinoma (PDAC) arises from the exocrine pancreas and accounts for the majority (~90 %) of pancreatic neoplasms [2]. Due to unique anatomical location and physiological characteristics  \nof pancreas, PDAC becomes one of the most challenging cancers to diagnose and treat. It is often detected at an advanced stage, and most current treatment options prove ineffective, resulting in a poor overall prognosis [3]. Despite significant attempts and research, there are still no effective treatments for PDAC at present. In light of this critical scenario, there is an urgent need for more precise and responsive early diagno","cbCaia9sO2VvABvB","https://ap.wps.com/l/cbCaia9sO2VvABvB","pdf",13232439,12,"English","# Introduction\n## Background: PDAC, tumor immunity, and metabolic reprogramming\n# Results (from abstract)\n## ENO1 expression and prognosis in PDAC\n## Effects of ENO1 knockdown in vitro and in vivo\n## ENO1 regulation of tumor immune microenvironment\n## Mechanism: PD-L1 upregulation via HIF-1α signaling\n# Conclusion","[{\"question\":\"What role does ENO1 play in PDAC progression?\",\"answer\":\"ENO1 promotes PDAC progression by increasing PD-L1 expression and thereby limiting CD8+ T cell infiltration and function in the tumor microenvironment.\"},{\"question\":\"How does ENO1 affect CD8+ T cells in the tumor immune microenvironment?\",\"answer\":\"High ENO1 expression impairs CD8+ T cell infiltration and function, weakening anti-tumor immunity.\"},{\"question\":\"What mechanism links ENO1 to PD-L1 expression?\",\"answer\":\"Mechanistic analysis indicates that ENO1 upregulates PD-L1 through the HIF-1α signaling pathway under hypoxic conditions.\"}]","ENO1 promotes PDAC progression - inhibiting CD8+ T cell infiltration via upregulating PD-L1 expression through HIF-1α signaling | PDF",1790180924,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4b1ede81402142080ee631463009b8dc.webp",983,1310,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6f139be25d0838f3de177bf82f933f7e.webp",982,1309,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6c4d6ea3fc03d75cc2024d5dfaf38367.webp",981,1308,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/da367d0cbeeefc352e829b2beacc66f1.webp",980,1306]